Non-Invasive Deep Brain Neuromodulation Patents: Top Companies & Trends 2026
- One assignee holds 10 of the ranked filings while the remaining ten ranked entities hold single-digit counts each, leaving a long tail of academic and individual filers.
- Filings peaked at 7 in 2021 and fell to 2 by 2024 (-71% over that span) — though 2025-2026 counts are still filling in under publication lag.
- 96.7% of the 30 records in scope sit in A61N and 93.3% in A61B, showing claim activity concentrated in electrotherapy and diagnostic/surgical delivery, not in materials or hardware classes.
Filing growth compares 2021 (7 records) with 2024 (2) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
What this landscape covers
This landscape tracks patent activity at the intersection of temporal interference stimulation and focused ultrasound neuromodulation, filtered to records that also address practical delivery problems: envelope modulation, focal depth control, skull aberration correction, thermal dose management, off-target activation, and session protocol design. The scope spans filings from 2015 through the 2026 data cut-off, covering 30 published records across 30 patent families.
Because these are still-developing delivery techniques rather than a settled device category, most of the record set falls under electrotherapy and surgical/diagnostic classifications rather than a dedicated neuromodulation subclass. That composition is itself informative: the field is being claimed as a therapeutic method and delivery technique, not primarily as a materials or component innovation.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
The filing trend and IPC composition below are drawn from the same 30-record set used throughout this page.
Filings rose to a 2021 peak, then declined
Annual filings moved from 5 in 2017 to a peak of 7 in 2021, then to 2 by 2024 — a -71% move over that three-year span. 2025 and 2026 figures are still incomplete because publication typically lags filing by roughly 18 months, so the apparent recent decline should not be read as the field cooling; it is partly an artefact of the lag.
Electrotherapy and surgical classes dominate
A61N (electrotherapy & radiation therapy) appears on 96.7% of the 30 records and A61B (diagnosis & surgery) on 93.3%, confirming this is claimed overwhelmingly as a therapeutic delivery technique. G01N (material analysis & testing) appears on 30.0% of records, likely reflecting dosimetry and calibration claims. A61M, B29C, C08F, C12N and H01L each appear on a single record (3.3%), marking small, largely unclaimed adjacent areas rather than active fronts.
Shares are the percentage of the 30 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Non-Invasive Deep Brain Neuromodulation with Eureka
This page is one run against one query. Ask Eureka your own question about non-invasive deep brain neuromodulation and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited filing in this set
Non-invasive focused ultrasound neuromodulation to treat physiological conditions (US20230140990A1)
The subject matter of the present disclosure generally relates to techniques for applying focused ultrasound energy to a region of interest in a subject to induce neuromodulation of the celiac plexus to treat inflammatory bowel disease. The region of interest may include at least a portion of a peripheral ganglion of the celiac plexus.Filed by GE Precision Healthcare LLC, published 2023-05-11.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20180028841A1 | Methods and systems for peripheral nerve modulation using focused ultrasound | 87 |
| 2 | US20200147415A1 | Methods and systems for selective modulation of motor neuronal activity in the peripheral nervous system | 9 |
| 3 | US20190247678A1 | Methods and systems for peripheral nerve modulation using focused ultrasound | 8 |
| 4 | WO2018022902A1 | Methods and systems for peripheral nerve modulation using focused ultrasound | 6 |
| 5 | US20230140990A1 | Non-invasive focused ultrasound neuromodulation to treat physiological conditions | 5 |
| 6 | US11013938B2 | Methods and systems for peripheral nerve modulation using non ablative focused ultrasound with electromyograp… | 4 |
| 7 | US20220175306A1 | Neuromodulation to target glucose transporter and/or incretin pathways | 1 |
| 8 | WO2020186073A1 | Neuromodulation to target glucose transporter and/or incretin pathways | 1 |
Ranked by citation count within this corpus; older records accumulate citations simply by being available longer, so treat this as a signal of influence rather than current relevance.
Publication numbers are shown where the record carries one (8 of 8 rows); clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns in this dataset matter more than the raw counts: where citation weight sits, how concentrated ownership is, and where technology classes are thin.
One early filing carries most of the citation weight
US20180028841A1, on peripheral nerve modulation using focused ultrasound, is cited 87 times against single digits for the next several records. That gap reflects its early filing date more than unique technical breadth — later, more specific filings simply haven't had time to accumulate citations.
Momentum has cooled from the 2021 peak, with a caveat
Annual filings fell from 7 in 2021 to 2 in 2024. That is a genuine three-year decline, but 2025-2026 numbers are still incomplete under the roughly 18-month publication lag, so it would be premature to call the field itself shrinking.
One assignee leads by a wide margin, the rest file once or twice
The ranking returns 11 companies; the leader holds 10 of the ranked filings while fifth and tenth place each hold 1. That is a single dominant filer sitting over a long tail of academic centres and individual inventors, not a crowded competitive field.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to non-invasive deep brain neuromodulation, with the prior art for and against each one.
Who is filing, and where the field is still open
The ranked leaders here are dominated by one corporate filer and a handful of universities and individual inventors; recent-year activity spreads across smaller, newer entrants.
GE Precision Healthcare leads by volume
The leading assignee's count separates it clearly from the rest of the ranked list, where fifth and tenth place each hold a single filing. Its representative filing extends focused ultrasound neuromodulation toward peripheral and autonomic targets, not solely central nervous system applications.
University systems anchor the long tail
Columbia, the University of Texas system, and West Virginia University's board of governors each appear in the ranking, typically with small, recent counts. These look like early-stage research filings rather than commercialisation-ready portfolios.
New individual filers are active but unconsolidated
Several individual inventors show a single filing in the latest year, with at least one co-filing pair among them. This pattern is typical of an early field: activity is dispersed and has not yet consolidated into competing corporate portfolios.
| Assignee | Recent year | YoY |
|---|---|---|
| West Virginia University Board of Governors on behalf of West Virginia University | 1 | — |
| MURUGAN MANAVALAN | 1 | — |
| M R JOSPINE SHINEY | 1 | — |
| LISHA DANIEL | 1 | — |
| General Electric Co | 0 | — |
| The Trustees of Columbia University in the City of New York | 0 | — |
| Albany Medical College | 0 | — |
| GE Precision Healthcare LLC | 0 | -100% |
Where to take this analysis
The filing trend and class composition point to a field still defining its core delivery methods, with several supporting technique areas left largely unclaimed.
Map the white space before filing
The under-claimed branches above — skull aberration correction, thermal dose feedback, and session protocol design — sit outside the dense A61N/A61B core and may offer clearer freedom to operate.
Explore white space in EurekaTrack the leader's next moves
With one assignee holding the bulk of the ranked filings, changes in its filing rate or new co-assignee pairings are the clearest early signal of where the field consolidates next.
Monitor assignee activity in EurekaCommon questions about this landscape
In this dataset it refers mainly to two technique families claimed as therapeutic methods: temporal interference stimulation and focused ultrasound neuromodulation. Filings in this space are classified overwhelmingly under A61N (electrotherapy) and A61B (diagnosis and surgery), meaning they are claimed as delivery methods and treatment protocols rather than as new materials or standalone hardware. The search scope also requires a practical delivery element — focal depth, skull aberration correction, thermal dose, off-target activation, or session protocol — so purely theoretical modelling patents fall outside it.
One assignee holds 10 of the 11 ranked filings, well ahead of the rest of the ranked list, where fifth and tenth place each hold a single filing. The remainder of the ranking is made up of university systems and individual inventors, each typically holding one or two filings. This is a concentration at the top with a long tail beneath it, not a broad competitive field with several evenly matched players.
Annual filings rose to a peak of 7 in 2021 and fell to 2 by 2024, a -71% move over that span. That decline is real for the 2021-2024 window, but counts for 2025 and 2026 are still incomplete because patent publication typically lags the actual filing date by around 18 months. Readers should not treat the most recent one to two years as evidence of a continuing slowdown until later data fills in.
That filing, held by GE Precision Healthcare LLC and published 2023-05-11, claims techniques for applying focused ultrasound energy to a region of interest to induce neuromodulation of the celiac plexus, aimed at treating inflammatory bowel disease. It is notable because it extends focused ultrasound neuromodulation to a peripheral, autonomic nervous system target rather than a purely central nervous system application. Anyone designing a focused ultrasound protocol targeting peripheral ganglia should review its claim scope closely before finalising a device or protocol design.
The technology composition shows dense claiming in A61N and A61B but only single-digit or single-record activity in areas like thermal dose feedback control, skull aberration correction algorithms, and session protocol standardisation. These are supporting techniques rather than the core stimulation methods, and the current filing record suggests they have not been comprehensively claimed. A first filing that combines one of these supporting techniques with a specific stimulation modality is more likely to find clear claim space than a filing on the core stimulation method itself.
Research Non-Invasive Deep Brain Neuromodulation in depth with Eureka
Go past this page: query the whole non-invasive deep brain neuromodulation corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.